Reckitt Benckiser Group plc (the "Company" or "RB") announces the following change in the interests of a Director in ordinary shares of 10 pence each in the share capital of the Company ("Shares").
The Company was notified on 27 February 2019 that Andrew Bonfield, Independent Non-Executive Director, purchased a total of 80 Shares on 27 February 2019 at £57.60 per share.
This was in relation to his 2018 remuneration. The remuneration of RB's Non-Executive Directors includes fees which are to be used in the purchase of Shares. Approximately 18% of the Non-Executive Directors' base fee (net) is invested in Shares which they are expected to retain for the duration of their tenure. The percentage of Andrew Bonfield's fees applied in this way were pro-rated based on his appointment to the Board on 1 July 2018.
Following this transaction, Mr Bonfield has a beneficial holding of 80 Shares in the Company, representing 0.00001% of the total voting rights of the Company.
The following notification is made in accordance with the requirements of the EU Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Details of the person discharging managerial responsibilities / person closely associated
Reason for the notification
Initial notification/ Amendment
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Reckitt Benckiser Group plc
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument
Ordinary shares of 10p each in Reckitt Benckiser Group plc
Nature of the transaction
Purchase of shares as part of requirement for percentage of base fee to invested in shares in relation to 2018 fees (following applicable withholdings in respect of any tax liability) (pro-rated based on 18% for NED)
Price(s) and volume(s)
- Aggregated volume
Date of the transaction
Place of the transaction
London Stock Exchange, Main Market - XLON
For further Information: Christine Logan
Deputy Company Secretary Tel +44 (0) 1753 217 800
SVP, Investor Relations
Tel. +44 (0)1753 217 800
Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108
RB* is the global leading consumer health, hygiene and home company. Driven by a purpose of providing innovative solutions for healthier lives and happier homes, RB has operations in over 60 countries. From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, its global brands help people live healthier, happier lives.
RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.
RB's unique culture is at the heart of its success. Its drive to achieve, passion to outperform and commitment to quality and scientific excellence is manifested in the work of over 40,000 employees worldwide.
*RB is the trading name of the Reckitt Benckiser group of companies
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...